Remove 2017 Remove Chemotherapy Remove Immunization
article thumbnail

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Of those who receive a transplant, about 50 percent will ultimately relapse, stated research from 2017, published in the journal Blood. Could CAR T therapies be manufactured in one day?

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 months in patients treated with chemotherapy. Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. billion (see below). months, compared with 6.7 Johnson and Johnson & Momenta.

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2017; 8(43): 75712–26.

article thumbnail

Progressing personalised cell therapies in oncology

European Pharmaceutical Review

Since 2017, six CAR-T cell therapies have been approved by the US Food and Drug Administration (FDA) for the treatment of blood cancers, including lymphomas, some forms of leukaemia, and, most recently, multiple myeloma. CAR T Cells: Engineering Immune Cells to Treat Cancer [Internet]. References National Cancer Institute. Cancer.gov.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

“If we work closely with government stakeholders and possibly collaborate on developing innovative access schemes for rare diseases, cancers, immune and inflammatory disorders, we can encourage greater participation by established biopharmas and stimulate the growth of entrepreneurial local companies in the region.”. million in 2030.

article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. AMR is already the third leading cause of death worldwide, causing around 1.27